Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Whole Genome Sequencing of Selected GeT-RM Coriell Samples with Consensus Calls for up to 28 Pharmacogenetics Genes

ABSTRACT: Polaris HiSeq X PGx Cohort

PROVIDER: PRJEB19931 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR1955330.fastq.gz	Fastqsanger.gz
	ERR1955330_1.fastq.gz	Fastqsanger.gz
	ERR1955330_2.fastq.gz	Fastqsanger.gz
	ERR1955340.fastq.gz	Fastqsanger.gz
	ERR1955340_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 210

Similar Datasets

HiSeq 4000 / 10X Whole Genome Sequencing of Selected GeT-RM Coriell Samples with Consensus Calls for up to 28 Pharmacogenetics Genes

Project description:Polaris HiSeq 4000 PGx 10X Cohort

| PRJEB26950 | ENA

Whole Genome Sequencing of 150 Coriell Samples of diverse ethnic backgrounds

Project description:Polaris HiSeq X Diversity Cohort

| PRJEB20654 | ENA

Whole Genome Sequencing of 50 Coriell Samples whose parents were sequenced as part of the Illumina Polaris HiSeqX Diversity panel (PRJEB20654)

Project description:Polaris HiSeq X Kids Cohort

| PRJEB25009 | ENA

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (ADOPT-PGx)

Project description:A Depression and Opioid Pragmatic Trial in Pharmacogenetics (ADOPT-PGx)

| PRJNA774419 | ENA

Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.

Project description:Pharmacogenetic testing is increasingly available from clinical laboratories. However, only a limited number of quality control and other reference materials are currently available to support clinical testing. To address this need, the Centers for Disease Control and Prevention-based Genetic Testing Reference Material Coordination Program, in collaboration with members of the pharmacogenetic testing community and the Coriell Cell Repositories, has characterized 137 genomic DNA samples for 28 genes commonly genotyped by pharmacogenetic testing assays (CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP4F2, DPYD, GSTM1, GSTP1, GSTT1, NAT1, NAT2, SLC15A2, SLC22A2, SLCO1B1, SLCO2B1, TPMT, UGT1A1, UGT2B7, UGT2B15, UGT2B17, and VKORC1). One hundred thirty-seven Coriell cell lines were selected based on ethnic diversity and partial genotype characterization from earlier testing. DNA samples were coded and distributed to volunteer testing laboratories for targeted genotyping using a number of commercially available and laboratory developed tests. Through consensus verification, we confirmed the presence of at least 108 variant pharmacogenetic alleles. These samples are also being characterized by other pharmacogenetic assays, including next-generation sequencing, which will be reported separately. Genotyping results were consistent among laboratories, with most differences in allele assignments attributed to assay design and variability in reported allele nomenclature, particularly for CYP2D6, UGT1A1, and VKORC1. These publicly available samples will help ensure the accuracy of pharmacogenetic testing.

| S-EPMC4695224 | biostudies-literature

Glucocorticoids Unmask Silent Non-Coding Genetic Risk Variants for Common Diseases [HiChIP]

Project description:30 B-lymphoblastoid cell lines (LCLs) with genome-wide genotype data were treated with hydrocortisone (GR agonist) and CORT108297 (GR modulator), followed by RNA-seq to identify PGx-eQTLs. We then integrated GR chromatin immunoprecipitation-sequencing (ChIP-seq) to characterize the epigenetic function of PGx-eQTLs that interfere with GR response elements. We also applied a high-throughput enhancer assay (STARR-seq) using PGx-eQTL loci DNA sequences to “scan” for drug-dependent SNPs.

2022-11-16 | GSE189453 | GEO

Glucocorticoids Unmask Silent Non-Coding Genetic Risk Variants for Common Diseases [STARR-seq]

2022-11-16 | GSE185939 | GEO

Glucocorticoids Unmask Silent Non-Coding Genetic Risk Variants for Common Diseases [ChIP-seq]

2022-11-16 | GSE185928 | GEO